Inclusion Criteria:

- Diagnosis of metastatic adenocarcinoma of the colon or rectum

- Available paraffin-embedded tumor tissue

- Failure of first line treatment containing fluoropyrimidine and oxaliplatin based
chemotherapy with bevacizumab for mCRC

- Measurable disease

- Adequate hematologic, renal, hepatic and metabolic function

Exclusion Criteria:

- Radiotherapy ≤ 2 weeks prior to Day 1 of Cycle 1

- Unresolved toxicity(ies) from prior anti cancer therapy that, in the opinion of the
investigator, precludes the subject from study enrollment

- Prior irinotecan therapy. anti EGFr therapy, or vaccine for the treatment of mCRC

- CYP3A4 enzyme inducers, inhibitors, and substrates (eg, phenytoin, phenobarbital,
carbamazepine, ketoconazole, rifampin, rifabutin, and St. John's Wort) ≤ 2 weeks
prior to Day 1 of Cycle 1

- Infection requiring systemic anti infectives completed ≤ 2 weeks prior to Day 1 of
Cycle 1

- Clinically significant cardiovascular disease

- History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis)

- Pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event ≤
8 weeks prior to Day 1 of Cycle 1

- Any significant bleeding ≤6 weeks prior to Day 1 of Cycle 1, per the investigator's
judgement

- Gastroduodenal ulcer(s) determined by endoscopy to be active or uncontrolled
gastrointestinal ulcer ≤ 4 weeks prior to Day1 of Cycle 1

- Any co morbid disease or condition that could increase the risk of toxicity (eg,
dihydropyrimidine deficiency, significant ascites, or pleural effusion)

- Major surgery (requiring general anesthesia), open biopsy, or significant traumatic
injury ≤4 weeks prior to Day1 of Cycle 1. Subjects must have recovered from surgery
and have no significant complications